Table 1.
All Patients |
Development of a Second Lung Primary |
||||||
---|---|---|---|---|---|---|---|
No |
Yes |
||||||
Characteristic | n | % | n | % | n | % | p Value |
Total | 156,494 | 151,872 | 4622 | ||||
Sex | <0.0001 | ||||||
Male | 83,971 | 53.7% | 81,653 | 53.8% | 2318 | 50.2% | |
Female | 72,523 | 46.3% | 70,219 | 46.2% | 2304 | 49.8% | |
Race | <0.0001 | ||||||
White | 125,762 | 80.4% | 121,921 | 80.3% | 3841 | 83.1% | |
Black | 17,392 | 11.1% | 16,911 | 11.1% | 481 | 10.4% | |
Other | 13,340 | 8.5% | 13,040 | 8.6% | 300 | 6.5% | |
Age at diagnosis, y | <0.0001 | ||||||
20-49 | 11,890 | 7.6% | 11,645 | 7.7% | 245 | 5.3% | |
50-59 | 28,866 | 18.4% | 27,908 | 18.4% | 958 | 20.7% | |
60-69 | 48,762 | 31.2% | 46,842 | 30.8% | 1920 | 41.5% | |
≥70 | 66,976 | 42.8% | 65,477 | 43.1% | 1499 | 32.4% | |
Histologic type | <0.0001 | ||||||
Squamous cell | 32,326 | 20.7% | 31,061 | 20.5% | 1265 | 27.4% | |
SCLC | 18,585 | 11.9% | 18,356 | 12.1% | 229 | 5.0% | |
Adenocarcinoma | 58,031 | 37.1% | 55,696 | 36.7% | 2335 | 50.5% | |
Other NSCLC | 47,552 | 30.4% | 46,759 | 30.8% | 793 | 17.2% | |
SEER stage | <0.0001 | ||||||
Local | 36,414 | 23.3% | 33,853 | 22.3% | 2561 | 55.4% | |
Regional | 49,568 | 31.7% | 47,965 | 31.6% | 1603 | 34.7% | |
Distant | 59,239 | 37.9% | 58,904 | 38.8% | 335 | 7.2% | |
Unstaged | 11,273 | 7.2% | 11,150 | 7.3% | 123 | 2.7% |
SEER, Surveillance, Epidemiology, and End Results.